Skip to main content
SanBio Co., Ltd. logo

SanBio Co., Ltd.

Tokyo, JapanSee on the mapFounded 2001

  • Series D
  • Stroke

SanBio is a biotechnology company developing regenerative cell medicines for central nervous system disorders, including traumatic brain injury and stroke. Its lead cell therapy, AKUUGO®, has received conditional, time-limited approval in Japan, and the company is preparing for its commercial launch while pursuing broader indications and global development.

Raised
$570M
Jan 2026
Series D
Investors
6
Founded
2001
Employees
11–50

reccy insights

Recent highlights

SanBio’s central focus is regenerative cell medicine for neurological conditions, including stroke and traumatic brain injury. The company is preparing for commercial launch while continuing broader indication and global development work. An undated growth signal identifies Dr. Shilpa Sambashivan as appointed CEO and board member, but gives no appointment date. Financing entries include a $287 million Series D dated January 2026, with RTW Investments, Hengdian Group, SR One, TCG Crossover, RA Capital Management, HBM Healthcare Investments, Invus, SilverArc Capital, and Adage Capital Management listed as lead investors. Earlier listed financing includes a $162 million Series D in January 2024.

Written by reccy's AI from company sites, press and funding records · updated Nov 2026

What makes SanBio Co., Ltd. distinct

  1. 01Focuses on regenerative cell medicines for neurological conditions with limited effective treatment options.
  2. 02AKUUGO® has received conditional, time-limited approval in Japan for a brain-related indication.
  3. 03Develops therapies intended to promote regenerative processes and restore lost motor or sensory function.
  4. 04Combines Japanese operations with a U.S. subsidiary and aims to advance regenerative medicine globally.

Technology & products4

  • AKUUGO® Suspension for Intracranial Implantation

    Regenerative cell medicine for a brain-related indication; it has received conditional, time-limited approval in Japan.

  • SB623

    Regenerative cell therapy in clinical development for chronic motor impairments following stroke and traumatic brain injury.

  • SB618

    Enhanced type-mesenchymal stem cells in development for peripheral neuropathy.

Recent updates3

  • Oct 7, 2026Product launch

    Notice Regarding the First Post-Marketing Administration of AKUUGO® Suspension for Intracranial Implantation

    sanbio.com
  • Dec 8, 2025Team change

    Appointment of Two Corporate Officers in the Quality Compliance & Regulatory Affairs Division and the Production Division

    sanbio.com
  • May 30, 2025Team change

    Keita Mori, Representative Director and President of SanBio, Appointed Chairman of Samurai Biotech Association

    sanbio.com

Funding

$570M disclosed
Latest valuation JPY 71.97B6 investors

Investors19

Also backed by
  • Mizuho Bank
  • 三菱UFJ信託銀行(株)
  • The Column Group
  • Samsara Bio Capital
  • Leaps by Bayer
  • Apeloa Pharmaceutical
  • Hengdian Group
  • SR One
  • HBM Healthcare Investments
  • Nissay Capital

About SanBio Co., Ltd.

Products
AKUUGO® Suspension for Intracranial Implantation, SB623, SB618, SB308
Leadership
Dr. Shilpa Sambashivan, CEO and board member
Focus areas
Regenerative medicine, cell therapy, neurology, central nervous system, tbi, stroke, biotechnology, clinical development
Headquarters
Tokyo, Japan
Founded
2001
Employees
11–50
Status
Active · public company